Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
Background. Several studies have reported that statins have anti-inflammatory effects. Nevertheless, results of clinical trials concerning the effect of statins on the levels of C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) have been inconsistent. Therefore, we performed a systematic review and meta-analysis of randomized clinical trials (RCTs) evaluating the effect of statins on CRP and hs-CRP levels in patients with cardiovascular diseases (CVDs). Methods. Literature search of the major databases was performed to find eligible RCTs assessing the effect of statins on serum levels of CRP and hs-CRP from the inception until the last week of April 2021. The effect sizes were determined for weighted mean difference (WMD) and 95% confidence intervals (CI). Results. 26 studies were identified (3010 patients and 2968 controls) for hs-CRP and 20 studies (3026 patients and 2968 controls) for CRP. Statins reduced the serum levels of hs-CRP ( WMD = − 0.97 mg / L ; 95% CI: -1.26 to -0.68 mg/L; P < 0.001 ) and CRP ( WMD = − 3.05 mg / L ; 95% CI: -4.86 to -1.25 mg/L; P < 0.001 ) in patients with CVDs. Statins decreased the serum levels of hs-CRP in patients receiving both high-intensity and moderate/low-intensity treatments with these drugs. In addition, the duration of treatment longer than 10 weeks decreased hs-CRP levels. Only high-intensity statin treatment could marginally decrease serum levels of CRP in CVDs patients. Conclusions. This meta-analysis showed the efficacy of statins to reduce the concentrations of CRP and hs-CRP in patients with different types of CVDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This has been confirmed in a recent meta-analysis that showed statins reduce hsCRP levels in patients with CV disease [6].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“to account for the effect of statins, which are known to reduce hsCRP levels [5, 6], a sensitivity analysis was conducted for the effect of treatment (semaglutide or comparators) on ratios to baseline by statin use (yes/no) at baseline.”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Accordingly, heterogeneity was considered significant if I2 was >50% and Cochrane’s Q was P < 0:10, while I2 < 50% and Cochrane’s Q (P > 0:10) did not prove a heterogeneity [41, 42].”
BackgroundQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Accordingly, heterogeneity was considered significant if I2 was >50% and Cochrane’s Q was P < 0:10, while I2 < 50% and Cochrane’s Q (P > 0:10) did not prove a heterogeneity [41, 42].”
BackgroundAtherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Jadad tool was used for evaluating the quality of RCTs by assessing the randomization, blinding, and dropouts (withdrawals) [40].”
MethodOperating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Intravenous Fluids and Acute Kidney Injury
Ding, X., Cheng, Z., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452702 · Cited by 6,827
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F., & Braunwald, E. (1999) · Circulation · doi:10.1161/01.cir.100.3.230 · Cited by 1,478
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Inflammation and cardiovascular disease mechanisms
Libby, P. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.456s · Cited by 1,104 · cited 5×
“In order to obtain a clear answer, we performed a systematic review and a meta-analysis of randomized controlled trials (RCTs) which evaluated the effects of statins in lowering CRP and hs-CRP levels in different types of CVDs, such as ACS, myocardial infarction (MI), coronary artery disease (CAD), unstable angina, he…”
BackgroundInfluentialKotseva, K., Wood, D., De Bacquer, D., De Backer, G., Rydén, L., Jennings, C., Gyberg, V., Amouyel, P., Bruthans, J., Castro Conde, A., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487315569401 · Cited by 1,006 · cited 1×
“Statins, which are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are broadly used as lipid-lowering drugs in patients with cardiovascular diseases (CVDs) [1, 2].”
BackgroundSelf-citationFerrario, C. M., & Strawn, W. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.059 · Cited by 512
Patti, G., Pasceri, V., Colonna, G., Miglionico, M., Fischetti, D., Sardella, G., Montinaro, A., & Di Sciascio, G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.025 · Cited by 483
A novel anti-inflammatory role for simvastatin in inflammatory arthritis.
Leung, B. P., Sattar, N., Crilly, A., Prach, M., McCarey, D. W., Payne, H., Madhok, R., Campbell, C., Gracie, J. A., Liew, F. Y., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1524 · Cited by 434
Node, K., Fujita, M., Kitakaze, M., Hori, M., & Liao, J. K. (2003) · Circulation · doi:10.1161/01.cir.0000084539.58092.de · Cited by 414 · cited 1×
“On the other hand, statins have antiinflammatory effects, and therefore, they might be beneficial in diseases related to inflammation including not only atherosclerosis [8] but also congestive heart failure (CHF) [9], nephropathy [10], central nervous system (CNS) diseases [11], autoimmune disease [12], sepsis [13], g…”
BackgroundKinlay, S., Schwartz, G. G., Olsson, A. G., Rifai, N., Leslie, S. J., Sasiela, W. J., Szarek, M., Libby, P., & Ganz, P. (2003) · Circulation · doi:10.1161/01.cir.0000091404.09558.af · Cited by 405
Sola, S., Mir, M. Q. S., Khan, B. V., Lerakis, S., & Tandon, N. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.088 · Cited by 324 · cited 4×
“All included studies were performed in this century, and they were performed in different countries including China, Taiwan, Korea, Lebanon, Japan, Australia, the USA, Brazil, Argentina, the UK, Ireland, Greece, Russia, Italy, Poland, Germany, Czech Republic, and Turkey.”
BackgroundInfluentialKoenig, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.113 · Cited by 315
Morrow, D. A., de Lemos, J. A., Sabatine, M. S., Wiviott, S. D., Blazing, M. A., Shui, A., Rifai, N., Califf, R. M., & Braunwald, E. (2006) · Circulation · doi:10.1161/circulationaha.106.628909 · Cited by 313
Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Zhou, Q., & Liao, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315684 · Cited by 294 · cited 1×
“Statins, which are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are broadly used as lipid-lowering drugs in patients with cardiovascular diseases (CVDs) [1, 2].”
BackgroundNeuroprotection mediated by changes in the endothelial actin cytoskeleton
Laufs, U., Endres, M., Stagliano, N., Amin-Hanjani, S., Chui, D.-S., Yang, S.-X., Simoncini, T., Yamada, M., Rabkin, E., Allen, P. G., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9639 · Cited by 282 · cited 1×
“On the other hand, statins have antiinflammatory effects, and therefore, they might be beneficial in diseases related to inflammation including not only atherosclerosis [8] but also congestive heart failure (CHF) [9], nephropathy [10], central nervous system (CNS) diseases [11], autoimmune disease [12], sepsis [13], g…”
BackgroundStatins and the COVID-19 main protease: in silico evidence on direct interaction
Reiner, Ž., Hatamipour, M., Banach, M., Pirro, M., Al-Rasadi, K., Jamialahmadi, T., Radenkovic, D., Montecucco, F., & Sahebkar, A. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.94655 · Cited by 263 · cited 1×
“On the other hand, statins have antiinflammatory effects, and therefore, they might be beneficial in diseases related to inflammation including not only atherosclerosis [8] but also congestive heart failure (CHF) [9], nephropathy [10], central nervous system (CNS) diseases [11], autoimmune disease [12], sepsis [13], g…”
BackgroundSelf-citationKones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259 · cited 1×
“Besides, polarization of M1 macrophage by CRP is a proinflammatory trigger in plaque formation which causes macrophage infiltration in both adipose tissue and atherosclerotic lesions [84, 85].”
BackgroundLovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells.
Agarwal, B., Bhendwal, S., Halmos, B., Moss, S. F., Ramey, W. G., & Holt, P. R. (1999) · PubMed · Cited by 251
Hydrophilic or Lipophilic Statins?
Climent, E., Benaiges, D., & Pedro-Botet, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.687585 · Cited by 241
Bauer, D. C., Mundy, G. R., Jamal, S. A., Black, D. M., Cauley, J. A., Ensrud, K. E., van der Klift, M., & Pols, H. A. P. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.2.146 · Cited by 206 · cited 1×
“On the other hand, statins have antiinflammatory effects, and therefore, they might be beneficial in diseases related to inflammation including not only atherosclerosis [8] but also congestive heart failure (CHF) [9], nephropathy [10], central nervous system (CNS) diseases [11], autoimmune disease [12], sepsis [13], g…”
BackgroundChruściel, P., Sahebkar, A., Rembek-Wieliczko, M., Serban, M.-C., Ursoniu, S., Mikhailidis, D. P., Jones, S. R., Mosteoru, S., Blaha, M. J., Martin, S. S., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.897 · Cited by 194
Self-citationBalk, E. M., Lau, J., Goudas, L. C., Jordan, H. S., Kupelnick, B., Kim, L. U., & Karas, R. H. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00011 · Cited by 185
Ferretti, G., Bacchetti, T., & Sahebkar, A. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.08.003 · Cited by 184
Self-citationC-Reactive Protein Induces Matrix Metalloproteinase-1 and -10 in Human Endothelial Cells
Montero, I., Orbe, J., Varo, N., Beloqui, O., Monreal, J. I., Rodríguez, J. A., Díez, J., Libby, P., & Páramo, J. A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.070 · Cited by 181
Parizadeh, S. M. R., Azarpazhooh, M. R., Moohebati, M., Nematy, M., Ghayour‐Mobarhan, M., Tavallaie, S., Rahsepar, A. A., Amini, M., Sahebkar, A., Mohammadi, M., et al. (2011) · Lipids · doi:10.1007/s11745-010-3517-x · Cited by 180
Self-citationSahebkar, A., & Watts, G. F. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.019 · Cited by 180
Self-citationSahebkar, A., Serban, C., Ursoniu, S., Mikhailidis, D. P., Undas, A., Lip, G. Y. H., Bittner, V., Ray, K. K., Watts, G. F., Hovingh, G. K., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-08-0620 · Cited by 180
Self-citationSahebkar, A., Kotani, K., Serban, C., Ursoniu, S., Mikhailidis, D. P., Jones, S. R., Ray, K. K., Blaha, M. J., Rysz, J., Toth, P. P., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.022 · Cited by 178
Self-citationSahebkar, A., & Watts, G. F. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6479-4 · Cited by 175
Self-citationSimvastatin Inhibits Inflammatory Properties of Staphylococcus aureus α-Toxin
Pruefer, D., Makowski, J., Schnell, M., Buerke, U., Dahm, M., Oelert, H., Sibelius, U., Grandel, U., Grimminger, F., Seeger, W., et al. (2002) · Circulation · doi:10.1161/01.cir.0000034048.38910.91 · Cited by 170 · cited 1×
“On the other hand, statins have antiinflammatory effects, and therefore, they might be beneficial in diseases related to inflammation including not only atherosclerosis [8] but also congestive heart failure (CHF) [9], nephropathy [10], central nervous system (CNS) diseases [11], autoimmune disease [12], sepsis [13], g…”
BackgroundMcMurray, J. J. V., Kjekshus, J., Gullestad, L., Dunselman, P., Hjalmarson, A., Wedel, H., Lindberg, M., Waagstein, F., Grande, P., Hradec, J., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.849117 · Cited by 163
Cardiovascular effects of statins, beyond lipid-lowering properties
Mihos, C. G., Pineda, A. M., & Santana, O. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.009 · Cited by 162
Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins
Rauch, U., Osende, J., Chesebro, J. H., Fuster, V., Vorchheimer, D. A., Harris, K., Harris, P., Sandler, D. A., Fallon, J. T., Jayaraman, S., et al. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00397-x · Cited by 158 · cited 1×
“Statins interfere with cholesterol synthesis in the liver cells and, therefore, decrease the levels of total cholesterol and lowdensity lipoprotein cholesterol (LDL-C) in serum [7].”
BackgroundMikhailidis, D., Undas, A., Lip, G., Muntner, P., Bittner, V., Ray, K., Watts, G., Hovingh, G. K., Rysz, J., Kastelein, J., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0937 · Cited by 156
Self-citationEffects of statins beyond lipid lowering: Potential for clinical benefits
Almuti, K., Rimawi, R., Spevack, D. M., & Ostfeld, R. J. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.05.056 · Cited by 154
HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats
Usui, H. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/18.2.265 · Cited by 139 · cited 1×
“On the other hand, statins have antiinflammatory effects, and therefore, they might be beneficial in diseases related to inflammation including not only atherosclerosis [8] but also congestive heart failure (CHF) [9], nephropathy [10], central nervous system (CNS) diseases [11], autoimmune disease [12], sepsis [13], g…”
BackgroundNew and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 127
Yun, K. H., Jeong, M. H., Oh, S. K., Rhee, S. J., Park, E. M., Lee, E. M., Yoo, N. J., Kim, N., Ahn, Y. K., & Jeong, J. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.06.055 · Cited by 124
C-Reactive Protein: Clinical and Epidemiological Perspectives
Salazar, J., Martínez, M. S., Chávez, M., Toledo, A., Añez, R., Torres, Y., Apruzzese, V., Silva, C., Rojas, J., & Bermúdez, V. (2014) · Cardiology Research and Practice · doi:10.1155/2014/605810 · Cited by 117 · cited 1×
“Atherosclerotic lesions also produce CRP [22].”
Relation of Statin Use to the 5-Year Incidence and Progression of Age-Related Maculopathy
Klein, R. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.8.1151 · Cited by 106 · cited 1×
“On the other hand, statins have antiinflammatory effects, and therefore, they might be beneficial in diseases related to inflammation including not only atherosclerosis [8] but also congestive heart failure (CHF) [9], nephropathy [10], central nervous system (CNS) diseases [11], autoimmune disease [12], sepsis [13], g…”
BackgroundCicero, A. F. G., Fogacci, F., Hernandez, A. V., Banach, M., & on behalf of the Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP) (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003121 · Cited by 105
Macin, S. M., Perna, E. R., Farías, E. F., Franciosi, V. A., Cialzeta, J., Brizuela, M., Medina, F., Tajer, C. D., Doval, H. C., & Badaracco, J. R. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.041 · Cited by 103
Lipinski, M. J., Cauthen, C. A., Biondi‐Zoccai, G., Abbate, A., Vrtovec, B., Khan, B. V., & Vetrovec, G. W. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.07.055 · Cited by 100 · cited 1×
“However, treatment with statins did not affect all-cause or cardiovascular mortality in patients with heart failure [80].”
BackgroundC-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction
Devaraj, S., Yun, J.-M., Adamson, G., Galvez, J., & Jialal, I. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp249 · Cited by 99
Red Yeast Rice for Hypercholesterolemia
Cicero, A. F. G., Fogacci, F., & Zambon, A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.056 · Cited by 99 · cited 1×
“The decrease in LDL-C is accompanied by a proportional decrease in hs-CRP [76].”
BackgroundRapid immunomodulation by rosuvastatin in patients with acute coronary syndrome
Link, A., Ayadhi, T., Böhm, M., & Nickenig, G. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl277 · Cited by 96 · cited 1×
“However, the results of some studies were inconsistent and inconclusive [38].”
ResultVahedian‐Azimi, A., Mohammadi, S. M., Heidari‐Beni, F., Banach, M., Guest, P. C., Jamialahmadi, T., & Sahebkar, A. (2021) · Archives of Medical Science · doi:10.5114/aoms/132950 · Cited by 89
Self-citationDiversity of Denizens of the Atherosclerotic Plaque: Not All Monocytes Are Created Equal
Libby, P., Nahrendorf, M., Pittet, M. J., & Swirski, F. K. (2008) · Circulation · doi:10.1161/circulationaha.108.783068 · Cited by 78 · cited 1×
“Besides, polarization of M1 macrophage by CRP is a proinflammatory trigger in plaque formation which causes macrophage infiltration in both adipose tissue and atherosclerotic lesions [84, 85].”
BackgroundDohi, T., Miyauchi, K., Okazaki, S., Yokoyama, T., Yanagisawa, N., Tamura, H., Kojima, T., Yokoyama, K., Kurata, T., & Daida, H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.001 · Cited by 77
Lipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
Bahrami, A., Bo, S., Jamialahmadi, T., & Sahebkar, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101024 · Cited by 71
Self-citationStatins and C-reactive protein: in silico evidence on direct interaction
Shakour, N., Ruscica, M., Hadizadeh, F., Cirtori, C., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.100304 · Cited by 67
Self-citationEffects of statins on the biological features of mesenchymal stem cells and therapeutic implications
Gorabi, A. M., Kiaie, N., Pirro, M., Bianconi, V., Jamialahmadi, T., & Sahebkar, A. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09929-9 · Cited by 65
Self-citationCorreia, L. C. L., Sposito, A. C., Lima, J. C., de Magalhães, L. P., Passos, L. C. S., Rocha, M. D. S., D’Oliveira, A., & Esteves, J. P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00630-1 · Cited by 54
Statins as anti-pyroptotic agents
Khalifeh, M., Penson, P. E., Banach, M., & Sahebkar, A. (2021) · Archives of Medical Science · doi:10.5114/aoms/141155 · Cited by 49
Self-citationAbulhul, E., McDonald, K., Martos, R., Phelan, D. M. J., Spiers, P., Hennessy, M., Baugh, J. A., Watson, C. J., O’Loughlin, C., & Ledwidge, M. T. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.002 · Cited by 46
Therapeutic Lowering of C-Reactive Protein
Jimenez, R. V., & Szalai, A. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.619564 · Cited by 46 · cited 1×
“Several approaches have been attempted to control inflammatory diseases by reducing the levels of serum CRP [29, 30].”
BackgroundKim, M. C., Ahn, Y., Jang, S. Y., Cho, K. H., Hwang, S. H., Lee, M. G., Ko, J. S., Park, K. H., Sim, D. S., Yoon, N. S., et al. (2011) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2011.26.3.294 · Cited by 43 · cited 1×
“They indicated that lipophilicity/hydrophilicity of statin did not have any effect on hs-CRP levels [83].”
BackgroundStrazhesko, I. D., Ткачева, О. Н., Akasheva, D. U., Dudinskaya, Е. N., Владимировна, П. Е., Pykhtina, V. S., Сергеевна, К. А., Кокшагина, Н. В., Шарашкина, Н. В., Викторович, А. М., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00347 · Cited by 39
Mast cell tryptase – Marker and maker of cardiovascular diseases
Mohajeri, M., Kovanen, P. T., Bianconi, V., Pirro, M., Cicero, A. F. G., & Sahebkar, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.008 · Cited by 38 · cited 5×
“In order to obtain a clear answer, we performed a systematic review and a meta-analysis of randomized controlled trials (RCTs) which evaluated the effects of statins in lowering CRP and hs-CRP levels in different types of CVDs, such as ACS, myocardial infarction (MI), coronary artery disease (CAD), unstable angina, he…”
BackgroundInfluentialSelf-citationLuo, Y., Jiang, D., Wen, D., Yang, J., & Li, L. (2004) · Heart and Vessels · doi:10.1007/s00380-004-0776-6 · Cited by 36
Marschang, P., Friedrich, G. J., Ditlbacher, H., Stoeger, A., Nedden, D. Z., Kirchmair, R., Dienstl, A., Pachinger, O. M., & Patsch, J. R. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.01.042 · Cited by 35
Ošťádal, P., Alan, D., Hájek, P., Horak, D., Vejvoda, J., Trefanec, J., Mates, M., & Vojáček, J. (2003) · Springer eBooks · doi:10.1007/978-1-4615-0298-2_7 · Cited by 33
Clinical relevance for lowering C-reactive protein with statins
Arévalo‐Lorido, J. C. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1197413 · Cited by 33
An, J., Shi, F., Liu, S., Ma, J., & Ma, Q. (2017) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivx172 · Cited by 30 · cited 1×
“A meta-analysis published in 2017 reported that pretreatment with statins was associated with lower levels of CRP postoperatively in patients who had coronary artery bypass graft surgery [82].”
BackgroundAzar, R. R., Badaoui, G., Sarkis, A., Kassab, R., Salamé, E., Klaymé, S., Naman, R., & Germanos, M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.093 · Cited by 29
Nakagomi, A., Seino, Y., Kohashi, K., Kosugi, M., Endoh, Y., Kusama, Y., Atarashi, H., & Mizuno, K. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1123 · Cited by 29
A systematic review and meta-analysis on the efficacy of statins in the treatment of atherosclerosis
Jia, J., Zhang, L., Wang, L., Ji, C., Xia, R., & Yang, Y. W. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1243 · Cited by 24 · cited 1×
“A most recent meta-analysis of 12 articles with 1,180 participants could not find any significant difference between patients treated with statins and those who were not treated when hs-CRP was concerned [78].”
BackgroundGorabi, A. M., Aslani, S., Imani, D., Razi, B., Sathyapalan, T., & Sahebkar, A. (2021) · Phytotherapy Research · doi:10.1002/ptr.7262 · Cited by 24 · cited 1×
“Several approaches have been attempted to control inflammatory diseases by reducing the levels of serum CRP [29, 30].”
BackgroundSelf-citationChan, K., Chou, H., Huang, C., & Chou, M. (2008) · Clinical Cardiology · doi:10.1002/clc.20181 · Cited by 23
Guo, S., Wang, R., Yang, Z., Li, K.-L., & Wang, Q. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.722 · Cited by 21
Ošťádal, P., Alan, D., Hajek, P., Horak, D., Vejvoda, J., Trefanec, J., Mates, M., & Vojacek, J. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1023499727477 · Cited by 20
Li, J., & Fang, C. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.049700 · Cited by 19
Suzuki, T., Nozawa, T., Sobajima, M., Igarashi, N., Matsuki, A., Fujii, N., & Inoue, H. (2008) · International Heart Journal · doi:10.1536/ihj.49.423 · Cited by 19
Yun, K. H., Shin, I.-S., Shin, S.-N., Choi, J. H., Kim, S. H., Rhee, S. J., Lee, E. M., Yoo, N. J., Kim, N., Oh, S. K., et al. (2011) · Korean Circulation Journal · doi:10.4070/kcj.2011.41.8.458 · Cited by 19
Gruzdeva, O. V., Учасова, Е. Г., Dyleva, Y. A., Евгеньевна, А. О., Каретникова, В. Н., & Барбараш, О. Л. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00324 · Cited by 18
Reduction of C-reactive protein by a single 80 mg of simvastatin in patients with unstable angina
Li, J., Wang, Y., Nie, S., Zhang, C., Li, Y., Hui, R., & Zhen, X. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.08.012 · Cited by 16
Doo, Y., Han, S.-J., Han, S.-W., Park, W.-J., Choi, S., Cho, G., Hong, K.-S., Han, K., Lee, N., Oh, D., et al. (2005) · Clinical Cardiology · doi:10.1002/clc.4960280206 · Cited by 16
Jiao, Y., Hu, F., Zhang, Z., Gong, K., Sun, X., Li, A., & Liu, N. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0335-1 · Cited by 16
Toth, P. P. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79485-3 · Cited by 15
Lewandowski, M., Kornacewicz‐Jach, Z., Millo, B., Zielonka, J., Czechowska, M., Kaliszczak, R., Płońska, E., Gorący, J., Kaźmierczak, J., & Naruszewicz, M. (2008) · PubMed · Cited by 15
Novel Biomarkers Associated with Incident Heart Failure in 10 106 Finnish Men
Jauhiainen, R., Jauhiainen, M., Vangipurapu, J., Kuulasmaa, T., Ala‐Korpela, M., Laakso, M., & Kuusisto, J. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13132 · Cited by 15
Implications on the Therapeutic Potential of Statins via Modulation of Autophagy
Gorabi, A. M., Kiaie, N., Aslani, S., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9599608 · Cited by 15
Self-citationYang, J., Li, X., Zhao, S., Li, J., Li, J., & Xie, X. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.12.029 · Cited by 14
Atorvastatin affects C-reactive protein levels in patients with coronary artery disease
Karaca, I., İlkay, E., Akbulut, M., Yavuzkır, M., Pekdemir, M., Akbulut, H., & Arslan, N. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001686 · Cited by 12
Clinical efficacy and safety of statin treatment after carotid artery stenting
Qiao, L., Wang, S., Jia, Q., Bian, J., Fan, Y.-M., & Xu, X. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1645149 · Cited by 8
Vasilieva, E., Kasyanova, O., & Shpektor, A. (2008) · Acute Cardiac Care · doi:10.1080/17482940802064970 · Cited by 5
Cited by
C-reactive protein: a target for therapy to reduce inflammation
Rizo-Téllez, S. A., Sekheri, M., & Filep, J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237729 · Cited by 182
Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review
Banait, T., Wanjari, A., Danade, V., Banait, S., & Jain, J. (2022) · Cureus · doi:10.7759/cureus.30225 · Cited by 176
The interplay of factors in metabolic syndrome: understanding its roots and complexity
Islam, M. S., Wei, P., Suzauddula, M., Nime, I., Feroz, F., Acharjee, M., & Pan, F. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01019-y · Cited by 169
Surma, S., Sahebkar, A., & Banach, M. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106596 · Cited by 112
Self-citationMosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91
“Finally, to account for the effect of statins, which are known to reduce hsCRP levels [5, 6], a sensitivity analysis was conducted for the effect of treatment (semaglutide or comparators) on ratios to baseline by statin use (yes/no) at baseline.”
BackgroundResult
Metadata
- Authors
- Kandelouei, T., Abbasifard, M., Imani, D., Aslani, S., Razi, B., Fasihi, M., Shafiekhani, S., Mohammadi, K., Jamialahmadi, T., Reiner, Ž., & Sahebkar, A.
- Affiliations
- University of Utah (US)
- Rafsanjan University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
- Tarbiat Modares University (IR)
- Mashhad University of Medical Sciences (IR)
- University Hospital Centre Zagreb (HR)
- Corresponding author
- Razi, Bahman
- Sahebkar, Amirhossein
- ORCID
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2022-01-28
- Volume
- 2022
- Pages
- 1-20
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC8816584
- OpenAlex
- W4210294380
- Cited by
- 136
- References
- 101
- Citations by year
- 2026: 18 · 2025: 35 · 2024: 38 · 2023: 30 · 2022: 14
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, high-sensitivity C-reactive protein, C-reactive protein, cardiovascular disease, anti-inflammatory activity, statin intensity, treatment duration
- MeSH terms
- C-Reactive Protein, Cardiovascular Diseases, Humans, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.